CARBOPLATIN INJECTION 10 MG
CARBOPLATIN : 10 MG · DIN 02366053 · OMEGA LABORATORIES LIMITED
Health Canada status: DORMANT
What is CARBOPLATIN INJECTION?
CARBOPLATIN INJECTION 10 MG contains CARBOPLATIN : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02366053, held by OMEGA LABORATORIES LIMITED, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as dormant, status dated 28-Jul-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CARBOPLATIN INJECTION used for?
Treatment of ovarian cancer of epithelial origin in first line therapy, and in second line therapy after other treatments have failed.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02366053 |
|---|---|
| Brand name | CARBOPLATIN INJECTION |
| Generic / active ingredient | CARBOPLATIN : 10 MG |
| Manufacturer | OMEGA LABORATORIES LIMITED |
| Strength | 10 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | L01XA02 CARBOPLATIN |
| AHFS class | 84:80.00 |
| Biosimilar | No |
| Health Canada status | DORMANT |
| Status date | 28-Jul-2020 |
| Original market date | 2011-05-13 00:00:00 |
How is it administered?
Adults: 400 mg/m2 as a single IV infusion over 15-60 minutes every 4 weeks. Reduce dose by 20-25% for risk factors or renal impairment.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store between 15°C and 25°C, protected from light.
How is it supplied?
Single use vials: 50 mg/5 mL, 150 mg/15 mL, 450 mg/45 mL, and 600 mg/60 mL.
Contraindications
Severe myelosuppression; pre-existing severe renal impairment; history of severe allergic reactions to carboplatin or other platinum-containing compounds.
Warnings and precautions
Potent drug; use only by experienced physicians. Myelosuppression is closely related to renal clearance. Monitor blood counts and renal/hepatic function regularly.
Is CARBOPLATIN in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by ACCORD HEALTHCARE INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code L01XA02 CARBOPLATIN. 3 of 10 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CARBOPLATIN INJECTION | 10 MG | LIQUID | TEVA CANADA LIMITED | MARKETED | DIN 02125439 |
| CARBOPLATIN INJECTION BP | 10 MG | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | DIN 02320371 |
| CARBOPLATIN INJECTION BP | 10 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02126680 |
| CARBOPLATIN INJECTION | 10 MG | SOLUTION | EUGIA PHARMA INC. | APPROVED | DIN 02535289 |
| CARBOPLATIN INJECTION | 10 MG | SOLUTION | AURO PHARMA INC | APPROVED | DIN 02528916 |
| CARBOPLATIN INJECTION LIQ 10MG/ML | 10 MG | LIQUID | DAVID BULL LABORATORIES (PTY) LTD. | CANCELLED POST MARKET | DIN 01990438 |
| CARBOPLATIN INJECTION, BP | 10 MG | SOLUTION | STRIDES PHARMA CANADA INC | APPROVED | DIN 02420228 |
| PARAPLATIN INJ 150MG/VIAL | 150 MG | POWDER FOR SOLUTION | BRISTOL LABS DIVISION OF BRISTOL-MYERS SQUIBB | CANCELLED POST MARKET | DIN 00680060 |
| PARAPLATIN-AQ INJ 10MG/ML | 10 MG | LIQUID | BRISTOL-MYERS SQUIBB CANADA | CANCELLED POST MARKET | DIN 00788759 |
Who else supplies CARBOPLATIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CARBOPLATIN appears in 38 registered pack listings across 5 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.